XERS - Xeris Biopharma Holdings, Inc.
About Xeris Biopharma Holdings, Inc. (https://www.xerispharma.com)
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| John Shannon | Chief Executive Officer & Director | 1962 | $1,355,969 USD |
| Kevin McCulloch | President & Chief Operating Officer | 1964 | $913,527 USD |
| Beth Hecht | Chief Legal Officer & Corporate Secretary | 1964 | $817,367 USD |
| Steven Pieper | Chief Financial Officer | 1977 | $796,183 USD |
| Anh Nguyen | Chief Medical Officer | 1975 | $653,703 USD |
| Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | – | – |
| Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | – | – |
| Kendal Korte | Senior Vice President of Human Resources | – | – |